✦ LIBER ✦

Phase I clinical trial with IL-2-transfected xenogeneic cells administered in subcutaneous metastatic tumours: clinical and immunological findings

✍ Scribed by Tartour, E; Mehtali, M; Sastre-Garau, X; Joyeux, I; Mathiot, C; Pleau, J M; Squiban, P; Rochlitz, C; Courtney, M; Jantscheff, P

Book ID: 111724400
Publisher: Nature Publishing Group
Year: 2000
Tongue: English
Weight: 392 KB
Volume: 83
Category: Article
ISSN: 0007-0920
DOI: 10.1054/bjoc.2000.1492

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Phase I clinical study applying autologo

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

✍ Schmidt-Wolf, I G H; Finke, S; Trojaneck, B; Denkena, A; Lefterova, P; Schwella, 📂 Article 📅 1999 🏛 Nature Publishing Group 🌐 English ⚖ 95 KB

Vaccination with autologous tumour antig

Vaccination with autologous tumour antigen-pulsed dendritic cells in advanced gynaecological malignancies: clinical and immunological evaluation of a phase I trial

✍ Juan Hernando, Tjoung-Won Park, Kirsten Kübler, Ruth Offergeld, Harald Schlebusc 📂 Article 📅 2002 🏛 Springer-Verlag 🌐 English ⚖ 176 KB

A clinical phase I/II trial with the mon

A clinical phase I/II trial with the monoclonal antibody cG250 (RENCAREX®) and interferon-alpha-2a in metastatic renal cell carcinoma patients

✍ M. Siebels; K. Rohrmann; R. Oberneder; M. Stahler; N. Haseke; J. Beck; R. Hofman 📂 Article 📅 2010 🏛 Springer-Verlag 🌐 English ⚖ 311 KB

Allogeneic retrovirally transduced, IL-2

Allogeneic retrovirally transduced, IL-2- and IFN-γ-secreting cancer cell vaccine in patients with hormone refractory prostate cancer—a phase I clinical trial

✍ T. H. Brill; H. R. Kübler; H. v. Randenborgh; F. Fend; H. Pohla; J. Breul; R. Ha 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 856 KB

## Abstract ## Background The purpose of this vaccine study was to determine the safety and feasibility of vaccination with an allogeneic prostate carcinoma cell line, LNCaP, expressing recombinant interleukin‐2 (IL‐2) and interferon‐γ (IFN‐γ) and to evaluate the efficacy of inducing tumor‐specifi